Polish company Infermedica has received $10.25 million in a Series A funding round led by the European Bank for Reconstruction and Development and German VC fund for digital health solutions Heal Capital. Existing investors Karma Ventures, Inovo Venture Partners and DreamIT Ventures also participated in the round, the company reports in a press release.
Founded in 2012, Infermedica develops machine learning and AI-tools for preliminary medical diagnosis and patient triage. The company provides four different products:
- Symptom Checker, an application that allows quickly analyzing patients symptoms and helping them to find the right care.
- Call Center Triage, a patient triage tool for call centres.
- Infermedica API allows companies to integrate its diagnostic capabilities into any website, app or telehealth system.
- COVID-19 Risk Assessment, a set of solutions designed to help quickly identify coronavirus symptoms and get reliable information regarding COVID-19 concerns.
Infermedica operates also in the B2B model by providing its services to medical insurance companies, telemedicine platforms, hospitals and health care systems. The company cooperates with over 60 partners including Microsoft, Allianz Partners, Canadian Global Excel, German Sana Kliniken, Portuguese Médis and Polish PZU. The solutions offered by Infermedica are available in 17 languages, writes MamStartup.
The new funds will help Infermedica to develop AI-based clinical decision support solutions for both patients and doctors, as well as expand commercial operations in the US and Germany, maintains the CEO of the company Piotr Orzechowski.
